MedTrace Logo

A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis

NCT04603027 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 249

Last updated 2022-12-19

Study results available
· View outcomes & findings →

Summary

This Phase 2 study has been designed to investigate the clinical safety and efficacy of EDP1815 and to identify an optimal dose in subjects with mild to moderate psoriasis.

Conditions

Interventions

DRUG

EDP1815

EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria

DRUG

Placebo

Placebo oral capsule

Sponsors & Collaborators

  • Evelo Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Benjamin Ehst, MD PhD · Oregon Medical Research Center

  • Douglas Maslin, MPhil MBBS · Evelo Biosciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-21
Primary Completion
2021-07-02
Completion
2021-12-06
FDA Drug
Yes

Countries

  • United States
  • Hungary
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04603027 on ClinicalTrials.gov